Electrocore’s Strong Revenue Growth and Strategic Expansion Justify Buy Rating
Electrocore (ECOR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula ...
Dupixent® (Dupilumab) Sbla Accepted For FDA Review For The Treatment Of Chronic ...
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity M ...